Intranet Areál web

Gliflozins in the treatment of non-diabetic models of chronic kidney disease and heart failure

Laboratory name: Experimental Hypertension

Project supervisor: RNDr. Ivana Vaněčková, DSc. (

PhD project: Gliflozins in the treatment of non-diabetic models of chronic kidney disease and heart failure

The new class of antidiabetic drugs, gliflozins (inhibitors of sodium-glucose transporter 2 – SGLT-2), exert their hypoglycaemic effects through the inhibition of the sodium-glucose transporter at renal proximal tubule promoting glucose and sodium excretion. This leads not only to a significant improvement in the control of blood glucose but also promotes the lowering of blood pressure and body weight both in diabetic patients and in experimental diabetic models. There is numerous experimental data on the effects of different gliflozins (empagliflozin, dapagliflozin, canagliflozin) in diabetic kidney and heart disease. However, the experiments in non-diabetic animals are relatively scarce. Therefore, the aim of the PhD project will be the study mechanisms of actions of these new class of antidiabetic drugs under non-diabetic conditions. 

Candidate’s profile (requirements):

We are looking for motivated candidates with master's degree in physiology, medicine or related fields. They should be fluent in English and interested in the work with experimental animals.


Hüttl et al, Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model, J Physiol Pharmacol, 71(5), 2020

Hojná et al: Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, a non-diabetic model of hypertension, Biomed Pharmacother. 2021;144:112246.

Trnovska J et al: Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress. Int J Mol Sci. 2021;22(19):10606